Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Inhibition of the Cardiac Sarcolemma Na+/Ca2+ Exchanger by Conformationally Constrained Small Cyclic Peptides

Daniel Khananshvili, Brenda Mester, Miriam Saltoun, Xiaolan Wang, Gilat Shaulov and David Baazov
Molecular Pharmacology January 1997, 51 (1) 126-131; DOI: https://doi.org/10.1124/mol.51.1.126
Daniel Khananshvili
Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv 69978, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brenda Mester
Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv 69978, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Saltoun
Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv 69978, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaolan Wang
Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv 69978, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilat Shaulov
Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv 69978, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Baazov
Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv 69978, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Positively charged cyclic peptides (three to seven amino acids) have been tested for their inhibitory effects on Na+/Ca2+ exchange in the cardiac sarcolemma vesicles. The lead structure of Phe-Arg-C̅y̅s̅-̅A̅r̅g̅-̅C̅y̅s̅-Phe-CONH2 (FRCRCFa) has been systematically modified for identification of important pharmacophores. In cyclic peptides (intramolecular S—S bond), the carboxyl terminal is locked with amide (CONH2), and positive charge is retained by one or two arginines, ornithines, or lysines. Thirty-five different cyclic peptides show IC50values in the range of 2–800 μm, suggesting that some specific structure-activity relationships may determine the inhibitory effects. Shortening of the FRCRCFa length to four amino acids decreases the inhibitory potency by 10–80-fold. The substitution of Arg2 or Arg4 in FRCRCFa with lysine or ornithine decreases the inhibitory potency by 5–12-fold, suggesting that both arginines are beneficial for inhibition. The substitution of Phe1 in FRCRCFa by 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid produces a potent inhibitor (IC50 = 2–4 μm). TheN-myristoylated FRCRCFa exhibits an inhibitory potency (IC50 = 8–10 μm) similar to that of the parent FRCRCFa peptide, thereby arousing a new possibility for the development of a cell-permeable blocker of the Na+/Ca2+ exchanger. d-Arg4 ord-Cys5 substitutions in FRCRCFa do not alter the inhibitory effect, whereas the l-to-dsubstitutions of other amino acids in FRCRCFa reduce the inhibitory potency by 4–5-fold. Thus, thel-to-d substitutions of Arg4 and/or Cys5 have a potential to increase the peptide stability to proteolytic degradation. The insertion of proline outside of the ring of FRCRCFa diminishes the inhibitory potency by 3–6-fold, whereas proline introduction into the ring decreases the inhibitory potency by 16–20-fold. The replacement of Cys3 and Cys5 in FRCRCFa with β,β-dimethylcystein has no significant effect on the inhibitory potency, suggesting that the S—S bond is not exposed to the interface of the peptide/receptor interaction. In conclusion, the current data support a proposal that the conformationally constrained Arg-C̅y̅s̅-̅A̅r̅g̅-̅C̅y̅s̅ structure is obligatory for inhibition of Na+/Ca2+ exchange, whereas hydrophobic additions at the carboxyl and amino ends have limited effects in increasing the inhibitory potency.

Footnotes

    • Received May 24, 1996.
    • Accepted October 1, 1996.
  • Send reprint requests to: Dr. Daniel Khananshvili, Tel-Aviv University, Sackler School of Medicine, P.O.B. 39040, Ramat-Aviv 69978, Israel. E-mail: dhanan{at}post.tau.ac.il

  • This work is supported by the Israeli Academy, the Israeli-USA Binational Foundation (B.S.F.), and the Israeli Ministry of Science and the Arts.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 51 (1)
Molecular Pharmacology
Vol. 51, Issue 1
1 Jan 1997
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of the Cardiac Sarcolemma Na+/Ca2+ Exchanger by Conformationally Constrained Small Cyclic Peptides
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Inhibition of the Cardiac Sarcolemma Na+/Ca2+ Exchanger by Conformationally Constrained Small Cyclic Peptides

Daniel Khananshvili, Brenda Mester, Miriam Saltoun, Xiaolan Wang, Gilat Shaulov and David Baazov
Molecular Pharmacology January 1, 1997, 51 (1) 126-131; DOI: https://doi.org/10.1124/mol.51.1.126

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Inhibition of the Cardiac Sarcolemma Na+/Ca2+ Exchanger by Conformationally Constrained Small Cyclic Peptides

Daniel Khananshvili, Brenda Mester, Miriam Saltoun, Xiaolan Wang, Gilat Shaulov and David Baazov
Molecular Pharmacology January 1, 1997, 51 (1) 126-131; DOI: https://doi.org/10.1124/mol.51.1.126
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Polypharmacology of CBL0137 in the African Trypanosome
  • Peptide-mediated differential signaling at GPR83
  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics